Compounded vs brand GLP-1: what the FDA says

By PepBloom · Sources checked 6 Nov 2026 · How we write these pages

Every quote on this page comes from FDA. Nothing here names or rates a pharmacy or seller. Brand facts are in Ozempic vs Wegovy vs Mounjaro vs Zepbound.

Is compounded semaglutide the same as Ozempic?

No. FDA says "compounded drugs are not FDA approved. This means the agency does not review compounded drugs for safety, effectiveness or quality before they are marketed" (FDA). FDA lists this as a red flag: a company that "makes claims such as the compounded drug is the same as an FDA-approved drug."

Some compounded semaglutide is a salt form. FDA says "these salt forms, including semaglutide sodium and semaglutide acetate, are different active ingredients than are used in the approved drugs," and that it is "not aware of any lawful basis for their use in compounding."

The approved brands are semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound).

Is there still a GLP-1 shortage?

No. FDA's timeline, quoted from its update for compounders:

Can pharmacies still compound semaglutide and tirzepatide?

Only within limits. FDA says: "When a drug shortage is resolved, FDA generally considers the drug to be commercially available" (FDA). The rules differ for the two kinds of compounder.

State-licensed pharmacies (section 503A). The drug must be "compounded for an individual patient based on receipt of a prescription." The pharmacy may not compound, "regularly or in inordinate amounts," drugs that "are essentially copies of a commercially available drug product." The exception is when "a prescriber determines and documents the compounded drug product contains a change that produces a significant difference" for a named patient. FDA says it does not intend to act against a compounder that "fills four or fewer prescriptions of that compounded drug product during a calendar month."

Adding an ingredient doesn't always change this. FDA says it may treat semaglutide combined with vitamin B12 as "essentially a copy" when it is given the same way, such as an injectable, at a similar strength.

Outsourcing facilities (section 503B). They can't compound from bulk ingredients unless the ingredient is on the 503B bulks list or the drug is on FDA's shortage list. FDA says neither semaglutide nor tirzepatide is on either list.

FDA's advice: "Compounded drugs should only be used in patients whose medical needs cannot be met by an FDA-approved drug" (FDA).

What problems has FDA reported with compounded GLP-1s?

As of May 31, 2026, FDA had received "990 reports of adverse events associated with compounded semaglutide" and "more than 730 reports of adverse events associated with compounded tirzepatide" (FDA). FDA says these are "likely" underreported, because state-licensed pharmacies that are not outsourcing facilities don't have to report them.

• Dosing errors. FDA received reports, "some requiring hospitalization," linked to "patients measuring and self-administering incorrect doses of the drug, and in some cases, health care professionals miscalculating doses."
• Fake pharmacies. FDA found compounded semaglutide and tirzepatide with false labels. "In some cases, the compounding pharmacies identified on the labels of the products do not exist."
• Warm shipments. FDA says not to use "any injectable GLP-1 drug that arrives warm or with insufficient refrigeration."
• "Research use" products. FDA warned companies selling semaglutide, tirzepatide, retatrutide, survodutide or mazdutide "falsely labeled 'for research purposes' or 'not for human consumption.'" It says these are "of unknown quality and may be harmful."
• Counterfeits. FDA is "aware of counterfeit Ozempic marketed in the U.S."

FDA also says retatrutide and cagrilintide "cannot be used in compounding under federal law."

How long can a compounded GLP-1 vial be used?

FDA's advice for multi-dose vials: "Discard the vial within 28 days after the first use, even if medication remains in the vial," even if the compounder's instructions say longer. It also says to "always use a new, sterile needle and syringe for each dose" (FDA). Limits for the brand pens are in the out-of-fridge date tool.

What are FDA's red flags for online sellers?

FDA's list of warning signs, quoted (FDA). Watch for a company that:

• "offers medicine at deep discounts or prices that seem too good to be true"
• "does not require a screening and prescription by a licensed doctor before providing medicine"
• "does not have a licensed doctor available to answer questions after you receive your medication"
• sends medicine that "looks different than what you've previously received," or "arrives in packaging that is broken or damaged or lacks instructions for use"
• "makes spelling errors on the label or provides incorrect addresses of the pharmacy"

FDA says patients "should obtain a prescription from their doctor and fill the prescription at a state-licensed pharmacy."

How do I report a problem to FDA?

Use MedWatch, FDA's adverse event reporting program, online or by fax at 1-800-FDA-0178. FDA's drug information line is 855-543-3784. Talk to your prescriber about any side effect, and see GLP-1 side effects across the labels for what the brand labels list.

Sources

1. FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss (content current as of Oct 1, 2026) FDA.gov, checked Nov 6, 2026
2. FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize (latest update Apr 1, 2026) FDA.gov, checked Nov 6, 2026
3. MedWatch: FDA safety information and adverse event reporting program FDA.gov, checked Nov 6, 2026

PepBloom is for tracking and education. It isn't medical advice. Talk to your prescriber.

PepBloom logs every shot, brand or not

Shots, side effects and refill reminders in one place.

Coming soon on the App Store